

HUMIDITY EFFECTS ON AMORPHOUS PHARMACEUTICALS

High energy x-ray investigations of water sorption

Chris Benmore and Rick Weber, X-ray Science Division, Advanced Photon Source, Argonne National Laboratory, IL, USA
Pam Smith and Steve Byrn, Improved Pharma, West Lafayette, IN, USA


ABSTRACT

The kinetics and disorder of hydration, or dehydration, of pharmaceutical hydrates is important in the processing and storage of drug products.

- Here we present *in-situ* high energy x-ray measurements of humidity induced structural effects in glassy indomethacin where dissolution rates of different phases vary.
- The more soluble amorphous solid form of indomethacin is not the most thermodynamically stable and has the propensity to revert to a more stable crystalline form, becoming less effective.
- Amorphous indomethacin is more likely to transform to the stable γ -phase at low humidity and the metastable α -phase at high humidity.
- Time-resolved pair distribution function (PDF) experiments were performed in a custom built humidity chamber, continuously measuring the amorphous structure as the material becomes saturated with water vapor prior to crystallization.

MOTIVATION

- Indomethacin is a model compound due to the wealth of information about the more soluble amorphous form. How does the presence of water vapor affect the crystallization process?




SAMPLE

- Cryoground amorphous Indomethacin was probed with x-rays just below a hole cut in a 2mm diameter polyimide tube and exposed to varying humidity levels.







HIGH ENERGY X-RAY DIFFRACTION

- Scattering experiments were performed on beamline 6-ID-D using an incident energy of 100 keV in transmission geometry.
- The custom environmental chamber (Electro-Tech Systems model 5503) maintained relative humidity levels to within $\pm 0.1\%$
- Measurements on fresh samples stored at ambient conditions ($RH \sim 26 \pm 1\%$) were carried out as a function of relative humidity at 7%, 40%, 60% and 80% RH and $22 \pm 1^\circ\text{C}$.
- Diffraction data were collected on a Varex CT4343 area detector continuously every 5 minutes (with a dark current performed every 25 minutes) for several hours using in house QXRD acquisition software.



RESULTS

- Non-linear changes in the diffuse scattering were observed at different humidity levels and as a function of time.
- As the amorphous indomethacin sample sorped water, the scattering cross section decreased with time.
- Subtle changes in the amorphous structure were monitored in the PDF and found to be primarily between 1.5-4Å.
- Low density surface water strongly hydrogen bonds to amorphous Indomethacin at RH=80% prior to crystallization.



CONCLUSIONS

- Time-resolved, high-energy x-ray PDF experiments confirm that subtle structural changes in organic **amorphous materials** at different humidities are measureable.
- Low density water** is observed to strongly hydrogen bond to amorphous Indomethacin at high humidity, with a structure very different to that of bulk water.
- Water soption at high humidity causes **enhanced hydrogen bonding** in the amorphous form. This encourages Indomethacin molecules to hydrogen bond through a carboxylic dimer in the α -phase.

NEXT STEPS

- To understand the role of water in the crystallization of amorphous pharmaceuticals as a function of **humidity and temperature**.
- Analyze the time resolved PDF data at low humidity to see how surface water hydrogen bonding leads to formation of the denser γ -phase.
- Separate the intra- and inter-molecular contributions to the PDF using the *xINTERPDF* software (Shi 2018) to model different conformations and their changes during the crystallization process.

REFERENCES

- M. Otsuka and H. Tanabe. *Drug Dev. Ind. Pharm.*, **38** (2010) 380.
- V. Andronis and G. Zografi. *Pharm. Sci.* **15(6)** (1998) 835.
- C. Shi, R. Teerakapibal, L. Yu and G.G.Z. Zhang. *IUCrJ* **4** (2017) 555.
- C. Shi, *J. Appl. Cryst.* **51(5)** (2018) 1498.
- C.J. Benmore, Chapter 9 in *Discovering & Developing Molecules with Optimal "Drug-Like" Properties*. AAPS, Springer. ISBN 978-1-4939-1398-5 (2015).
- ACKNOWLEDGEMENTS** Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R44GM117701. This research used resources of the Advanced Photon Source, a U.S. DOE Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.